[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369828-105":59,"doc-detail-369828-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gut-dysbiosis-in-cancer-immunotherapy-microbiota-mediated-resistance-and-emerging-treatments","Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments","","Cancer is a multifaceted disease shaped by genetic predisposition, environmental drivers, and lifestyle habits. As cancer research accelerates, the gut microbiome has emerged as a key regulator of immunity and health. Dysbiosis—loss of microbial diversity and expansion of pathobionts—has been linked to inflammation, oncogenesis, angiogenesis, and metastasis. This review covers cancer-associated microbial species and tumorigenic pathways, highlights diagnostic methods for dysbiosis detection, and explains how gut dysbiosis reduces immunotherapy efficacy and promotes resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gut-dysbiosis-in-cancer-immunotherapy-microbiota-mediated-resistance-and-emerging-treatments/369828/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gut-dysbiosis-in-cancer-immunotherapy-microbiota-mediated-resistance-and-emerging-treatments/369828.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is gut dysbiosis and why does it matter in cancer?","Question",{"text":112,"@type":113},"Gut dysbiosis refers to loss of microbial diversity, growth of pathobionts, or decreased commensal microorganisms. It is linked to inflammation and cancer progression, and it can influence treatment response.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does gut dysbiosis contribute to resistance to cancer immunotherapy?",{"text":117,"@type":113},"Gut dysbiosis can diminish the efficacy of cancer treatments, including immunotherapies. It promotes immunotherapy resistance by altering drug metabolism and driving immunometabolic reprogramming that helps tumors evade immune attack.",{"name":119,"@type":110,"acceptedAnswer":120},"Which diagnostic and therapeutic approaches are discussed for dysbiosis-related cancer risk?",{"text":121,"@type":113},"The review highlights diagnostic tools such as metagenomics, metabolomics, and dysbiosis indexes for detecting gut bacterial imbalances. It also discusses microbiome-targeting strategies including fecal microbiota transplantation and probiotics to mitigate dysbiosis-related cancer progression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369828,1790197239,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Review  \nPUBLISHED 25 August 2025  \nDOI 10.3389/fimmu.2025.1575452  \nOPEN ACCESS  \nEDITED BY  \nRen-You Gan,  \nThe Hong Kong Polytechnic University, China  \nREVIEWED BY  \nEmma Berta Gutie´rrez Cirlos, National Autonomous University of Mexico, Mexico Yuting Ke,  \nMassachusetts Institute of Technology, United States  \n*CORRESPONDENCE  \nSumaira Anjum  \n [sumaira.anjum@kinnaird.edu.pk](sumaira.anjum@kinnaird.edu.pk)[ ](sumaira.anjum@kinnaird.edu.pk)Elham Abdullatif M. Sharif  \n [e.sharif@qu.edu.qa](e.sharif@qu.edu.qa)[ ](e.sharif@qu.edu.qa)Wisam Nabeel Ibrahim  \n [w.ibrahim@qu.edu.qa](w.ibrahim@qu.edu.qa)  \nRECEIVED 12 February 2025  \nACCEPTED 04 August 2025  \nPUBLISHED 25 August 2025  \nCITATION  \nEiman L, Moazzam K, Anjum S, Kausar H, Sharif EAM and Ibrahim WN (2025)  \nGut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments.  \nFront. Immunol. 16:1575452 .  \ndoi: 10.3389/fimmu.2025.1575452  \nCOPYRIGHT  \n© 2025 Eiman, Moazzam, Anjum, Kausar, Sharif and Ibrahim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nGut dysbiosis in cancer immunotherapy: microbiotamediated resistance and emerging treatments  \nLiza Eiman 1, Khadija Moazzam 1, Sumaira Anjum 1*, Humera Kausar 1, Elham Abdullatif M. Sharif 2* and Wisam Nabeel Ibrahim 2*  \n1 Department of Biotechnology, Kinnaird College for Women, Lahore, Pakistan, 2 Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar  \nCancer is a multifaceted disease driven by a complex interplay of genetic predisposition, environmental factors and lifestyle habits. With the accelerating pace of cancer research, the gut microbiome has emerged as a critical modulator of human health and immunity. Disruption in the gut microbial populations and diversity, known as dysbiosis, has been linked with the development of chronic inﬂammation, oncogenesis, angiogenesis and metastasis. This review discusses the microbial species associated with various types of cancer and the pathways involved in their tumorigenic effect including mechanisms like inﬂammatory cytokine response, immune modulation, genotoxicity and modiﬁcation of the tumor microenvironment. Diagnostic tools such as metagenomics, metabolomics, and the use of dysbiosis indexes help in the detection of gut bacterial imbalances, enabling early detection of cancer and potential intervention. Gut dysbiosis diminishes the efﬁcacy of cancer treatments including immunotherapies, and creates immunotherapy resistance by altering drug metabolism and driving immunometabolic reprogramming, allowing tumor cells to evade immune attack. Immunometabolic reprogramming through gut microbiota modulation provides a new avenue to be explored that can restore anti-tumor immunity and reverse resistance to cancer treatments. This review also highlights the use of fecal microbiota transplantation and probiotics to mitigate chances of dysbiosis-related cancer progression. Through a comprehensive assessment of the role of gut microbiota in cancer, this review underscores the need for the use of gut microbial biomarkers for cancer detection and microbiome-targeting strategies to individualize cancer treatment.  \nKEYWORDS  \ngut dysbiosis, cancer, microbiota, immunotherapy, tumor microenvironment, therapeutic potential  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nThe human body is a bustling metropolis of microscopic inhabitants who work silently to keep us healthy. These unsung workers are the gut microbiota, with 100 trillion microbes, including bacteria, fungi","cbCaiamci90MLsSc","https://ap.wps.com/l/cbCaiamci90MLsSc","pdf",2873934,26,"English","# 1 Introduction\n# 2 Gut microbiota\n## 2.1 Composition and diversity","[{\"question\":\"What is gut dysbiosis and why does it matter in cancer?\",\"answer\":\"Gut dysbiosis refers to loss of microbial diversity, growth of pathobionts, or decreased commensal microorganisms. It is linked to inflammation and cancer progression, and it can influence treatment response.\"},{\"question\":\"How does gut dysbiosis contribute to resistance to cancer immunotherapy?\",\"answer\":\"Gut dysbiosis can diminish the efficacy of cancer treatments, including immunotherapies. It promotes immunotherapy resistance by altering drug metabolism and driving immunometabolic reprogramming that helps tumors evade immune attack.\"},{\"question\":\"Which diagnostic and therapeutic approaches are discussed for dysbiosis-related cancer risk?\",\"answer\":\"The review highlights diagnostic tools such as metagenomics, metabolomics, and dysbiosis indexes for detecting gut bacterial imbalances. It also discusses microbiome-targeting strategies including fecal microbiota transplantation and probiotics to mitigate dysbiosis-related cancer progression.\"}]","Gut dysbiosis in cancer immunotherapy: microbiota-mediated resistance and emerging treatments | PDF",1790184769,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fda07979e9df33865c6288e819727242.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bf0da0576db54d153bea1193a625ea7.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/978c5f7be37c780ada23b6b946509fc8.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad6d52efd8a68c66c53e29dfcda14e12.webp",980,1385]